ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Dr. Fizazi discusses potential benefit of triplet therapy for metastatic hormone-sensitive prostate cancer"
Episode Synopsis
In this episode, Urology Times® Assistant Editor Janelle Hart spoke with Karim Fizazi, MD, PhD, about results from a game-changing study that was presented at the 2022 ASCO Genitourinary Cancers Symposium. The phase 3 ARASENS trial improved overall survival in patients with metastatic hormone-sensitive prostate cancer with triplet therapy. Fizazi is a medical oncologist and head of the department of cancer medicine at the Institute of Gustave Roussy, and professor of oncology at the University of Paris Sud in Villejuif, France.
More episodes of the podcast Urology Times Podcasts
Speaking of Urology: Patient-centered insights from the PKIDS trial in pediatric stone disease
09/10/2025
The Expert APProach: Training to Retain APPs in Urology, with J. Brandon Arruda, APRN, AGNP-C, CUNP
03/10/2025
Pearls & Perspectives: Theranostics and Beyond in Prostate Cancer, with Vahan Kassabian, MD
23/09/2025
In God we trust